PatchTheCVECVE-2025-4762: Insecure Direct Object Reference (IDOR) vulnerability in the eSignaViewer component in eSigna product versions
CVE-2025-4762 is a low-severity flaw (CVSS 2.0) affecting affected software. Below: why it ranks where it does, which versions are affected, what to do, and the exact commands.
Insecure Direct Object Reference (IDOR) vulnerability in the eSignaViewer component in eSigna product versions 1.0 to 1.5 on all platforms allow an unauthenticated attacker to access arbitrary files in the document system via manipulation of file paths and object identifiers.
Why this priority
- No elevated risk signals yet
No fix is published yet: follow the downgrade or mitigation steps.
Risk facts
| CVSS score | 2.0 (Low) |
| Attack vector | Network (remote) |
| Attack complexity | High |
| Privileges needed | Low |
| User interaction | Active |
| EPSS exploit chance | 0.3% (top 73%) |
| CISA exploited list | No |
| Weakness | CWE-20 |
| Published | 2025-05-15 |
| Last modified | 2026-06-17 |
Last updated 2026-06-17 · Sources: CVE Program, NVD, CISA KEV, EPSS and vendor advisories · How we score
Timeline
- Published CVE record published
- Updated Record last modified
Scores and fixes here are computed automatically from those and other public sources. Confirm with the vendor advisory before changing production systems.
Quick answers
How do I fix CVE-2025-4762?
No fixed release is listed yet. Watch the vendor advisory and apply any mitigation shown on this page.
Is CVE-2025-4762 being exploited?
CVE-2025-4762 is not on the CISA Known Exploited Vulnerabilities list at the time of the last update. Check again, as this can change.
What does CVE-2025-4762 affect?
CVE-2025-4762 affects affected software. Severity is low (CVSS 2.0). Insecure Direct Object Reference (IDOR) vulnerability in the eSignaViewer component in eSigna product versions 1.0 to 1.5 on all platforms allow an unauthenticated attacker to access arbitrary files in the document system via manipulation o
How urgent is CVE-2025-4762?
Priority 14/100. No elevated risk signals yet.